Skip to main content

2 Result(s)

within Chikako Nakai Remove this filter English Remove this filter

and

  1. Article

    Open Access

    Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

    Oncogenic mutations in BRAF genes are found in approximately 5–10% of colorectal cancers. The majority of BRAF mutations are located within exons 11–15 of the catalytic kinase domains, with BRAF V600E accounting ...

    Chikako Nakai, Sachiyo Mimaki… in International Journal of Clinical Oncology (2023)

    Download PDF (2026 KB) View Article

  2. Article

    Open Access

    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

    Patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) have a poorer prognosis as well as resistance to anti-EGFR antibodies. However, it is unclear whether BRAF mutations other than BRAFV600E (BRAFn...

    Eiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, Kei Muro… in British Journal of Cancer (2017)

    Download PDF (525 KB) View Article